Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16340495 | 0.95 | HTR6 (0.46) | HTR6SIGMAR1HTR7 | |
| SCHEMBL11625947 | 0.93 | HTR6 (0.45) | HTR6SIGMAR1HTR7 | |
| SCHEMBL1822774 | 0.89 | HTR6 (0.50) | HTR6SIGMAR1HTR7TDP1 | |
| SCHEMBL3874874 | 0.88 | HTR6 (0.53) | HTR6SIGMAR1HTR7 | |
| SCHEMBL3868123 | 0.88 | HTR6 (0.53) | HTR6SIGMAR1HTR7 | |
| SCHEMBL31121639 | 0.84 | HTR6 (0.56) | HTR6SIGMAR1HTR7 | |
| SCHEMBL2338975 | 0.84 | HTR6 (0.56) | HTR6SIGMAR1HTR7 | |
| SCHEMBL14290594 | 0.82 | SIGMAR1 (0.55) | SIGMAR1 | |
| SCHEMBL16340383 | 0.81 | HTR6 (0.47) | HTR6SIGMAR1HTR7 | |
| SCHEMBL20430497 | 0.81 | HTR6 (0.47) | HTR6SIGMAR1HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11059818-B2 | Triazolopyridine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-13 | — | — | US | disclosed |
| US-20200291015-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2020-09-17 | — | — | US | disclosed |
| WO-2017160632-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-21 | — | — | WO | disclosed |
| US-4172945-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1979-10-30 | — | — | US | disclosed |
| US-4138497-A | Indanpentol derivatives for treating hypertension | E. R. SQUIBB & SONS, INC. (US) | 1979-02-06 | — | — | US | disclosed |
| US-4127578-A | Diene intermediates for indantetrols | E. R. SQUIBB & SONS, INC. (US) | 1978-11-28 | — | — | US | disclosed |
| US-4092318-A | HYPOTENSIVES | E. R. SQUIBB & SONS, INC. (US) | 1978-05-30 | — | — | US | disclosed |
| US-4053596-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1977-10-11 | — | — | US | disclosed |
| US-4044040-A | HYPERTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1977-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291015-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | MPO, NOX5, SERPINB1 | HTR6 4423/4885SIGMAR1 2852/4885HTR7 4188/4885 |
| US-11059818-B2 | Triazolopyridine inhibitors of myeloperoxidase | MPO, NOX5, SERPINB1 | HTR6 4423/4885SIGMAR1 2852/4885HTR7 4188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.